Literature DB >> 832510

Pharmacokinetics of fosfomycin.

W M Kirby.   

Abstract

Fosfomycin, an antibiotic discovered in Spain, has a unique chemical structure and pharmacologic features that are promising for clinical therapy. It is only partially absorbed orally, with relatively low blood levels. Intramuscularly, however, absorption is complete with peak blood levels 3-5 times as high as orally, and rapid intravenous injections give serum concentrations almost twice as high as intramuscularly. Some accumulation occurs with all three routes, and concentrations in excess of 1,000 mug/ml are consistently obtained in the urine with parenteral doses every 6 h. The serum half-life is 1.5-2 h, urinary excretion is by glomerular filtration, the antibiotic is not bound to serum proteins, and the volume of distribution is large. Diffusion into tissues and body fluids is good. Thus, the pharmacologic characteristics of fosfomycin along with its low toxicity make it comparable in these respects to other well-established antibiotics.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832510     DOI: 10.1159/000222040

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  28 in total

Review 1.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 2.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

3.  Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.

Authors:  M Frossard; C Joukhadar; B M Erovic; P Dittrich; P E Mrass; M Van Houte; H Burgmann; A Georgopoulos; M Müller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci.

Authors:  A Ferrara; C Dos Santos; M Cimbro; G Gialdroni Grassi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

5.  Factors influencing the activity of the trometamol salt of fosfomycin.

Authors:  D Greenwood; A Jones; A Eley
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

6.  Comparison of fosfomycin and vancomycin therapy for experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.

Authors:  A Rodríguez; M V Vicente; T Olay
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

7.  Activity of the trometamol salt of fosfomycin in an in vitro model of the treatment of bacterial cystitis.

Authors:  D Greenwood
Journal:  Infection       Date:  1986 Jul-Aug       Impact factor: 3.553

8.  [Fosfomycin concentrations in serum and bile (author's transl)].

Authors:  O Müller; U Rückert; W Walter; R Haag; W Sauer
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

9.  Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity.

Authors:  T Bergan
Journal:  Infection       Date:  1990       Impact factor: 3.553

10.  Fosfomycin trometamol: historical background and clinical development.

Authors:  G Gialdroni Grassi
Journal:  Infection       Date:  1990       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.